Paired kidney analysis of tacrolimus and cyclosporine microemulsion-based therapy in Chinese cadaveric renal transplant recipients

Transplant International

Volumn 19, Issue 8, 2006, Pages 657-666

  Chi, Yuen Cheung ^a   Kim, Ming Wong ^a   Hoi, Wong Chan ^a   Yan, Lun Liu ^a   Yiu, Han Chan ^a   Ho, Sing Wong ^a   Wai, Leung Chak ^a   Koon, Shing Choi ^a   Ka, Foon Chau ^a   Chun, Sang Li ^a  

^a QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

Creatinine clearance; Cyclosporine; Paired kidney; Tacrolimus

Indexed keywords

ANTIHYPERTENSIVE AGENT; AZATHIOPRINE; BASILIXIMAB; CREATININE; CYCLOSPORIN A; DACLIZUMAB; HYDROCORTISONE; METHYLPREDNISOLONE; PREDNISOLONE; TACROLIMUS;

ACNE; ACUTE GRAFT REJECTION; ADULT; AREA UNDER THE CURVE; ARTICLE; CADAVER DONOR; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GINGIVA HYPERPLASIA; GRAFT RECIPIENT; HIRSUTISM; HONG KONG; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KAPOSI SARCOMA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MICROEMULSION; NEUROTOXICITY; OPEN STUDY; OPPORTUNISTIC INFECTION; PARESTHESIA; POSTTRANSPLANT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STOMACH CARCINOMA; TITRIMETRY; TREMOR; URINARY TRACT INFECTION;

ACUTE DISEASE; ADULT; CHINA; CYCLOSPORINE; EMULSIONS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL RATE; TACROLIMUS;

EID: 33745685284     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2006.00335.x     Document Type: Article

References (48)

1. Calne RY, Rolles K, White DJ, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 1979; 2: 1033.
2. European Multicentre Trial Group. Cyclosporine in cadaveric renal transplantation: one-year follow-up of a multicentre trial. Lancet 1983; 2: 986.
3. Ball BM, Tiller DJ, Hardie I, et al. Comparison of three immunosuppressive regimens in cadaveric renal transplantation: long-term cyclosporine, short-term cyclosporine followed by azathioprine and prednisolone, and azathioprine and prednisolone without cyclosporine. N Engl J Med 1998; 318: 1499.
4. The Canadian Multicentre Transplant Study Group. A randomized clinical trial of cyclopsorine in a cadaveric renal transplantation. N Engl J Med 1983; 309: 809.
5. Friman S, Backman L. A new microemulsion formulation of cyclosporine: pharmacokinetic and clinical features. Clin Pharmacokinet 1996; 30: 181.
6. Keown P, Niese D, on behalf of the International Sandimmun Neoral Study Group. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. Kidney Int 1998; 54: 938.
7. Niese D, on behalf of the International Sandimmun Neoral Study Group. A double-blind randomized study of Sandimmun Neoral versus Sandimmun in new renal transplant recipients: results after 12 months. Transplant Proc 1995; 27: 1849.
8. Pollard SG, Lear PA, Ready AR, Moore RH, Johnson RWG, on behalf of the UK Neoral Renal Study Group. Comparison of microemulsion and conventional formulations of cyclosporin A in preventing acute rejection in de novo kidney transplant patients. Transplantation 1999; 68: 1325.
9. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977.
10. Mayer AD, Dmitrewski J, Squifflet JP, et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group. Transplantation 1997; 64: 436.
11. Jensik SC and the FK 506 Kidney Transplant Study Group. Tacrolimus (FK506) in kidney transplantation: three-year survival results of the US Multicenter, Randomized, Comparative Trial. Transplant Proc 1998; 30: 1216.
12. Vincenti F and the Tacrolimus Kidney Transplant Study Group. Tacrolimus (FK506) in kidney transplantation: five-year survival results of the US Multicenter, Randomized, Comparative Trial. Transplant Proc 2001; 33: 1019.
13. Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomized trials. BMJ 1999; 318: 1104.
14. Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomized trial data. BMJ 2005; 331: 810.
15. Ghasemian SR, Light JA, Currier C, Sasaki TM, Aquino A. Tacrolimus vs Neoral in renal and renal/pancreas transplantation. Clin Transplant 1999; 13: 123.
16. Morris-Stiff G, Ostrowski K, Balaji V, et al. Prospective randomized study comparing tacrolimus (Prograf) and cyclosporine (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. Transpl Int ????; 11(Suppl. 1): S334.
17. Jurewicz WA. Immunological and non-immunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. Transplant Proc 1999: 31(Suppl. 7A): 64S.
18. Boots JMM, van Duijnhoven E, Christiaans M, Nieman FHM, van Suylen RJ, van Hooff JP. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients. Transpl Int 2001; 14: 370.
19. Gurkan A, Tuncer M, Colak T, et al. Comparison of tacrolimus and Neoral-based immunosuppressive regimens in renal transplantation patients: single-center experience. Transplant Proc 2002; 34: 1661.
20. Pascual J, Marcen R, Burgos FJ, et al. One-center comparison between primary immunosuppression based on Neoral cyclosporine and tacrolimus for renal transplantation. Transplant Proc 2002; 34: 94.
21. Margreiter R for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplantation Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomized multicenter study. Lancet 2002: 359: 741.
22. Trompeter R, Filler G, Webb NJA, et al. Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantation. Pediatr Nephrol 2002; 17: 141.
23. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775.
24. Mayer AD for the European Tacrolimus Multicenter Renal Study Group. Chronic rejection and graft half-life: five-year follow-up of the European Tacrolimus Multicenter Renal Study. Transplant Proc 2002: 34: 1491.
25. Hohage H, Bruckner D, Arlt M, Buchholz B, Zidek W, Spieker C. Influence of cyclosporine A and FK506 on 24 hour blood pressure monitoring in kidney transplant recipients. Clin Nephrol 1996; 45: 342.
26. Wong KM, Shek CC, Chau KF, Li CS. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J kidney Dis 2000; 35: 660.
27. Stolk L, Van Duijnhoven EM, Christiaans MHL, van Hooff JP. Trough levels of tacrolimus (discussion). Ther Drug Monit 2002; 24: 573.
28. Pisitkun T, Elam-Ong S, Chusil S, Praditpornsilpa K, Pansin P, Tungsanga K. The roles of C4 and AUC 0-4 in monitoring of tacrolimus in stable kidney transplant patients. Transplant Proc 2002; 34: 3173.
29. Keown P, Kahan BD, Johnston A. Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the International Neoral TDM Advisory Consensus Meeting (Vancouver, November 1997). Transplant Proc 1998; 30: 1645.
30. Gaspari F, Caruso R, Cattaneo D, Perico N, Remuzzi G. Optimization of cyclosporine therapy in the Neoral era: abbreviated AUC, single blood sampling? Transplant Proc 2001; 33: 3117.
31. Meier-Kriesche HU, Alloway R, Gaber AO, Canafax DM, Kaplan B. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients. J Clin Pharmacol 1999; 39: 166.
32. Tsang WK, Ho YW, Tong KL, Chan WH, Chan A. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients. Transplant Proc 1996; 28: 1330.
33. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148.
34. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
35. Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine (editorial). Nephron 1992; 62: 249.
36. Mahalati K, Kahan BD. Pharmacological surrogates of allograft outcome. Ann Transplant 2000; 5: 14.
37. Macchi-Andanson M, Charpiat B, Jelliffe RW, Ducerf C, Fourcade N, Baulieux J. Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit 2001; 23: 129.
38. Scholten EM, Cremers SCLM, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 2005; 67: 2440.
39. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55.
40. Van Gelder T, Warle M, Ter Meulen RG. Anti-interleukin-2 receptor antibodies in transplantation: what is the basis for choice? Drugs 2004; 64: 1737.
41. Mihatsch MJ, Kyo M, Morozumi K, Yamaguchi Y, Nickeleit V, Ryffel B. The side effects of cyclosporin A and tacrolimus. Clin Nephrol 1998; 49: 356.
42. Kaplan B, Schold JD, Meier-Kriesche H. Long-term graft survival with Neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003; 14: 2980.
43. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 16;130: 461.
44. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137.
45. Zuo L, Ma YC, Zhou YH, Wang M, Xu GB, Wang HY. Application of GFR-estimating equations in Chinese patients with chronic kidney disease. Am J Kidney Dis 2005; 45: 463.
46. Klein IHHT, Abrahams A, van Ede T, Hene RJ, Koomans HA, Ligtenberg G. Different effects of Tacrolimus and Cyclosporine on renal haemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732.
47. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004; 78: 242.
48. Miyagi M, Ishikawa Y, Mizuiri S, Aikawa A, Ohara T, Hasegawa A. Significance of subclinical rejection in early renal allograft biopsies for chronic allograft dysfunction. Clin Transplant 2005; 19: 456.